Ingenia Therapeutics Begins KOSDAQ Trading to Advance Vascular-Targeted Therapy Pipeline
Ingenia Therapeutics, a clinical-stage biotechnology company focused on developing next-generation vascular-targeted therapies, has announced that its shares have begun trading on South Korea’s KOSDAQ market, marking a significant milestone in the company’s development and growth strategy.
The initial public offering is expected to provide Ingenia with additional resources to accelerate the clinical development and potential global commercialization of its proprietary pipeline of therapies designed to address diseases associated with vascular dysfunction. The company plans to use proceeds from the IPO to advance clinical programs, expand its research activities and strengthen its portfolio across ophthalmology, chronic kidney disease and oncology.
Founded in Boston in 2018, Ingenia Therapeutics is developing antibody-based medicines designed to target vascular biology through technologies originating from the Korea Advanced Institute of Science and Technology (KAIST) and the Institute for Basic Science (IBS).
The company has built its research strategy around two principal technology platforms, TIE-body and LCIDEC (Ligand Capture & Internalization into Endothelial Cells). Together, these technologies are intended to provide new approaches for stabilizing damaged blood vessels and selectively addressing disease-associated proteins.
Ingenia believes that improving vascular stability could offer therapeutic benefits across a broad range of diseases in which abnormal vascular function contributes to disease progression.
Focus on Vascular Stabilization
Blood vessel stability plays an important role in maintaining healthy tissue function. Dysfunction of the vascular system can contribute to inflammation, leakage, tissue damage and disease progression across multiple therapeutic areas.
Ingenia’s TIE-body technology is designed to directly activate TIE2, a receptor that plays an important role in maintaining vascular stability. By stimulating TIE2 signaling, the company aims to strengthen the vascular barrier and improve the integrity of damaged blood vessels.
The second platform, LCIDEC, is designed to stabilize damaged vasculature while also enabling targeted removal of disease-causing proteins. The approach is based on ligand capture and internalization into endothelial cells, potentially providing a mechanism for selectively addressing pathological proteins involved in vascular disease.
The company believes these technologies can provide a foundation for developing medicines that address the underlying biology of vascular disorders rather than focusing exclusively on downstream symptoms.
IGT-427 Represents a Key Late-Stage Program
One of Ingenia’s most advanced assets is IGT-427 (MK-8748), an investigational bispecific antibody designed to combine TIE2 agonism with VEGF inhibition.
The therapy is being evaluated in late-stage clinical development for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Both conditions involve abnormal blood vessel activity in the retina and can lead to vision impairment. Current treatment approaches commonly focus on inhibiting vascular endothelial growth factor, or VEGF, to reduce abnormal blood vessel growth and vascular leakage.
Ingenia’s approach seeks to go beyond VEGF inhibition by directly activating TIE2, with the goal of improving the stability and integrity of the retinal vasculature.
The company believes this dual mechanism could potentially provide benefits over conventional treatment approaches by simultaneously addressing vascular leakage and the underlying instability of the retinal blood vessels.
IGT-427 is being developed through a collaboration that has evolved alongside significant developments in the biotechnology sector.
Collaboration With EyeBio and Merck
In 2022, Ingenia entered into a research collaboration and licensing agreement with EyeBio involving its vascular-targeted technology and the development of IGT-427.
In 2024, EyeBio was acquired and subsequently became a wholly owned subsidiary of Merck, known as MSD outside the United States and Canada. As a result, the program became part of Merck’s broader ophthalmology development activities.
The collaboration highlights the potential commercial and scientific interest in therapies that combine vascular stabilization with established mechanisms such as VEGF inhibition.
As IGT-427 progresses through late-stage clinical trials, its development could provide additional validation for Ingenia’s TIE2-focused technology and potentially expand treatment options for patients with retinal vascular diseases.
The program also provides Ingenia with an important opportunity to demonstrate the broader applicability of its vascular stabilization platform in clinical settings.
Expanding Into Chronic Kidney Disease
While IGT-427 represents an important late-stage program, Ingenia is also advancing additional candidates in other therapeutic areas.
One of the company’s mid-stage assets is IGT-303, which is being developed for chronic kidney disease (CKD).
IGT-303 is currently being evaluated in a Phase 2a clinical trial across Australia, New Zealand and South Korea. The international clinical development program reflects Ingenia’s intention to establish its candidates as potential global therapies rather than limiting development to a single regional market.
The company is targeting potential global out-licensing opportunities for IGT-303 in 2027.
Chronic kidney disease represents another therapeutic area where vascular dysfunction and damage to the microvasculature can contribute to disease progression. Ingenia’s vascular-focused approach could therefore potentially provide a new mechanism for addressing aspects of CKD.
The company plans to use proceeds from its KOSDAQ listing to accelerate development of IGT-303 and prepare the program for future partnering opportunities.
Building an Oncology Pipeline
Ingenia is also applying its vascular biology expertise to oncology through IGT-532, an investigational therapy for solid tumors.
The candidate is advancing toward clinical development and is being designed as a novel oncology treatment intended to potentially provide improved efficacy compared with conventional VEGF/PD-1 bispecific antibodies.
Tumor blood vessels play an important role in cancer biology. Abnormal tumor vasculature can contribute to tumor growth, immune suppression and resistance to therapy. By targeting vascular mechanisms, Ingenia believes its technology could potentially provide a differentiated approach to treating solid tumors.
The advancement of IGT-532 represents an important step in the company’s effort to diversify its pipeline beyond ophthalmology and renal disease.
The program also illustrates the potential breadth of the company’s underlying vascular-targeting technologies, which may be applicable to diseases involving abnormal or damaged blood vessels across multiple therapeutic categories.
Preclinical Programs Expand Pipeline Diversity
Ingenia’s development strategy also includes earlier-stage programs targeting additional diseases.
The company is advancing IGT-302, a preclinical candidate for glaucoma, as well as IGT-627, a preclinical program focused on pulmonary arterial hypertension (PAH).
Both programs are being developed within the company’s broader strategy of applying vascular stabilization technology to diseases in which vascular dysfunction contributes to pathology.
Glaucoma is a significant ophthalmic disease in which progressive damage to the optic nerve can result in vision loss. Pulmonary arterial hypertension, meanwhile, involves abnormal narrowing and remodeling of the pulmonary arteries, placing increased strain on the heart.
The development of candidates in these areas could further expand Ingenia’s addressable market while providing additional opportunities to validate its proprietary platforms.
Global Research Collaborations
Ingenia is supporting its research activities through collaborations with academic and scientific institutions.
The company has ongoing research partnerships with organizations including Harvard Medical School and Emory University School of Medicine.
These collaborations are intended to support the development and evaluation of new vascular-targeted therapies and help advance the scientific understanding underlying Ingenia’s technology platforms.
Academic partnerships can also provide biotechnology companies with access to specialized research expertise, disease models and scientific capabilities that complement internal development programs.
For Ingenia, such collaborations are part of its broader strategy to build a globally competitive biotechnology platform around vascular biology.
KOSDAQ Listing Provides New Growth Platform
The beginning of trading on KOSDAQ represents a significant corporate milestone for Ingenia Therapeutics.
The IPO provides the company with additional capital at an important point in its development, as multiple programs are progressing through clinical and preclinical stages.
Ingenia plans to use the funding to accelerate clinical development, expand its pipeline and prepare selected programs for future global commercialization and partnering opportunities.
The company expects its public-market status to provide greater visibility among investors, potential strategic partners and the broader biotechnology community.
For a clinical-stage biotechnology company, access to capital is particularly important because advancing therapies through clinical development requires substantial investment in research, clinical trials, regulatory activities and manufacturing.
The KOSDAQ listing provides Ingenia with an additional financial platform as it moves toward these milestones.
CEO Highlights Strategic Importance
Sangyeul Han, PhD, Chief Executive Officer of Ingenia Therapeutics, described the KOSDAQ listing as a transformative milestone for the company.
Han said the company aims to help drive a shift in the treatment of vascular diseases through its proprietary technologies and emphasized Ingenia’s commitment to scientific development, clinical execution and long-term value creation.
The company intends to use the new resources to advance key clinical milestones across its portfolio while continuing to develop additional applications for its vascular stabilization technologies.
Ingenia Therapeutics enters its next phase as a publicly traded biotechnology company with a diversified pipeline spanning several important therapeutic areas.
Its most advanced program, IGT-427, is being evaluated in late-stage development for nAMD and DME through a partnership involving Merck’s EyeBio subsidiary. At the same time, IGT-303 is advancing through Phase 2a development for chronic kidney disease, while IGT-532 is moving toward clinical testing in solid tumors.
The company is also developing earlier-stage programs targeting glaucoma and pulmonary arterial hypertension and continues to work with leading academic institutions to expand its research capabilities.
The combination of TIE-body and LCIDEC technologies provides the foundation for Ingenia’s development strategy. By targeting vascular stability and the removal of disease-associated proteins, the company is seeking to create therapies that could potentially address the underlying biological mechanisms of multiple diseases.
The KOSDAQ listing provides Ingenia with new capital and a broader platform from which to advance these programs. As clinical development progresses, upcoming milestones across its ophthalmology, kidney disease and oncology portfolios will be important indicators of the potential of its technology.
With its public-market debut complete, Ingenia is now positioned to focus on translating its vascular-targeted research into clinical-stage therapies and, ultimately, potential treatments for patients with significant unmet medical needs.
About Ingenia Therapeutics
Ingenia Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies that restore the vascular stability. Headquartered in Watertown, MA, USA, with operations in South Korea and Australia, the company leverages its expertise in antibody engineering to target the TIE2 pathway across ophthalmology, nephrology, oncology and other high-value therapeutic areas, including CNS and Cardiovascular & Pulmonary diseases.